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Tumor protectionHutchinson–Gilford progeria syndrome (HGPS) patients do not develop cancer despite a signiﬁcant accumula-
tion of DNA damage in their cells. We have recently reported that HGPS cells are refractory to experimental on-
cogenic transformation and we identiﬁed the bromodomain-containing 4 protein (BRD4) as a mediator of the
transformation resistance. ChIP-sequencing experiments revealed distinct genome-wide binding patterns for
BRD4 in HGPS cells when compared to control wild type cells. Here we provide a detailed description of the
ChIP-seq dataset (NCBI GEO accession number GSE61325), the speciﬁc and common BRD4 binding sites between
HGPS and control cells, and the data analysis procedure associatedwith the publication by Fernandez et al., 2014
in Cell Reports 9, 248-260 [1].
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell
line/tissueHomo sapiens/dermal ﬁbroblast cell lines expressing
transforming factors from HGPS and age-matched
control individualsSex Male and female cell lines
Sequencer or array type Illumina HiSeq 2000
Data format Fastq
Experimental factors HGPS vs. wild type
Experimental features ChIP-seq, transcription factor binding sites, peak difﬁng
Consent NA
Sample source location Original cell lines were obtained from Coriell InstituteDirect link to deposited data
Deposited data can be found at: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE61325.rnandezferrp@mail.nih.gov
al Eye Institute, NIH, Bethesda
r Research UK London Research
C2A 3PX, UK and UCL Cancer
UK.
ss article under the CC BY-NC-ND liceExperimental design, materials and methods
The overall aim was to identify speciﬁc and common genomic bind-
ing sites for BRD4 in experimentally transformed dermal ﬁbroblasts de-
rived from HGPS patients and control individuals through the analysis
of BRD4 ChIP-sequencing data.
Cell culture
Transformed cell lines were obtained by retroviral introduction of
TERT (T), V12-HRAS (R) and SV40 large and small T antigens (S) of pri-
mary dermal ﬁbroblasts from HGPS patients (TRS-HGPS) and age-
matched controlwild-type individuals (TRS-WT) as previously described
[1–3]. Cells were grown in MEM containing 15% fetal bovine serum
(FBS), 2mM L-glutamine, 100 Uml−1 penicillin and 100 μgml−1 strepto-
mycin, at 37 °C in 5% CO2. Two independent cell lines from each group
were selected for ChIP-sequencing experiments.
ChIP-sequencing
ChIP was performed as previously described [4] with modiﬁcations.
Brieﬂy, 10 × 106 cells were cross-linked for 10 min with formalin 1% at
room temperature, followed by 5 minute quenching with 125 mM gly-
cine. After three washes with chilled PBS, cell pellets were snap-frozen
and stored at−80 °C. Cells were resuspended in lysis buffer containing
1 mM EDTA, 0.8% SDS, 20 mM Tris–HCl pH 8 and protease inhibitornse (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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12–15 cycles (30 s on, 60 s off). Chromatin was diluted in ChIP dilution
buffer (1% Triton X-100, 1 mM EDTA, 20 mM Tris–HCl pH 8, 150 mM
NaCl and protease inhibitor cocktail) and immunoprecipitated over-
nightwith pre-coated anti-IgGmagnetic beads (Dynabeads, Invitrogen)
previously incubated with anti-BRD4 antibody (7 μg, Bethyl labs, lot
A301-985) for 6 h at 4 °C. Beads were washed sequentially for 5 min
each in low-salt (20 mM Tris–HCl pH 8, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.1% SDS), high-salt (20 mM Tris–HCl pH 8, 500 mM
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), LiCl (10 mM Tris
pH 8.0, 1 mM EDTA, 250 mM LiCl, 1% NP-40, 1% Na-deoxycholate) and
TE (10 mM Tris–HCl pH 8, 1 mM EDTA) buffer at 4 °C followed by a
room temperature wash in TE buffer. Beads were eluted in 1% SDS and
100 mM NaHCO3 buffer for 25 min at 65 °C and cross-linking was re-
versed for 8 h after addition of NaCl (ﬁnal concentration 200 mM).
After RNase A (1 mg/ml, Qiagen) and proteinase K (2 mg/ml,
New England Biolabs) incubations, DNAwas column-puriﬁed following
the manufacturer's instructions (Qiaquick PCR puriﬁcation kit, Qiagen).
Library construction (Illumina TruSeq 2.0 protocol) and sequencing
were performed at the NCI-Sequencing Facility (SAIC-Frederick, MD)
using Illumina HiSeq 2000. Paired-end sequencing with read lengths
of 100 bp was performed. 4 input samples and 4 BRD4-ChIP samples
(from TRS-WT and TRS-HGPS cells, two independent cell lines in each
group) were multiplexed in two lanes. Raw reads ﬁles in fastq format
were deposited to the SRA database at NCBI (Table 1).Fig. 1. Flow chart of data analysis.ChIP-seq data analysis
The data analysis procedure is described in Fig. 1. The raw reads data
quality was tested using FastQC [5] (V0.10.1). All samples showed all
base quality ≥25 and a small number of TruSeq adapter sequences was
detected in the WT1 BRD4 reads. Raw reads of each sample in fastq for-
mat were then aligned to reference human genome (hg19) using
NovoalignMPI (V3.0.2, Novocraft) and the adapter sequence contamina-
tion in WT1 BRD4 sample was removed during mapping using “-a” op-
tion in command line. In addition, the program was instructed to only
report the uniquely aligned reads by skipping the “-r” option. The map-
ping results in BAM format were preprocessed using Picard tools [6]
(V1.119) to reorder, sort reads and the duplicated reads were removed
as well. The clean bam ﬁles were in turn converted to bed format using
“bamToBed” script in bedtools [7] (V2.19) in order to be analyzed
using SICER [8] (V1.1). Given the reported binding nature of BRD4 [9],
200 bpwindow size and 400 bp gap size were chosen in the peak calling
step using SICER. Statistically signiﬁcant peaks were detected using 1%
FDR as the cutoff. Peak numbers from each sample are shown in Table 2.
Peak signals were visualized using Integrative Genomics Viewer
(IGV) [10] for basic quality check; in addition, DiffBind [11] was applied
to the peak data to examine the correlation of WT and HGPS samples
using all default settings. In order to investigate potential differences
in BRD4 binding patterns in WT and HGPS samples, a pipeline wasTable 1
Sample names and their corresponding raw read ﬁle names in NCBI SRA archive database.
File names Sample names Group
SRR1574701 HG1 Input TRS-HGPS cells
SRR1574702 HG2 Input TRS-HGPS cells
SRR1574697 HG1 BRD4 TRS-HGPS cells
SRR1574698 HG2 BRD4 TRS-HGPS cells
SRR1574699 WT1 Input TRS-WT cells
SRR1574700 WT2 Input TRS-WT cells
SRR1574695 WT1 BRD4 TRS-WT cells
SRR1574696 WT2 BRD4 TRS-WT cellsdeveloped to detect sample-speciﬁc BRD4 bindings. First, the union
of the peaks in each biological group was calculated using the
“ﬁnd_union_islands.py” script in SICER, and then the intersection of
peaks in each group was achieved using the “intersect” command in
bedtools, and ﬁnally, the sample-speciﬁc peaks were derived by com-
paring the union peak sets with the intersected peak sets from different
samples using “-v” option in the “intersect” command. In this way, 3078
WT-speciﬁc and 5574 HGPS-speciﬁc BRD4 binding sites were detected
and the annotation of the peaks was done using “annotatePeaks.pl”
with default options in Homer [12]. Important genomic features
e.g., promoter, 5′/3′ UTR, exon, intron, non-coding were used to anno-
tate the peaks and differential enrichment in speciﬁc features were
compared between wild type and HGPS samples, as interpreted in [1].
Common BRD4 binding sites were detected by “multiinter” command
in bedtools and annotated using Homer. All annotated speciﬁc and
common genomic binding sites between WT and HGPS cell lines are
provided in Tables 3–5.Table 2
Number of peaks from each sample detected by SICER.
Samples WT1 WT2 HG1 HG2
Peaks 29990 32239 35292 42784
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